Mateus Fernando 4
4 · ABBOTT LABORATORIES · Filed Feb 23, 2022
Insider Transaction Report
Form 4
Mateus Fernando
Senior Vice President
Transactions
- Tax Payment
Common shares without par value
2022-02-21$116.79/sh−701$81,870→ 17,846 total - Tax Payment
Common shares without par value
2022-02-22$116.79/sh−886$103,476→ 16,960 total - Award
Option (right to buy)
2022-02-18+48,852→ 48,852 totalExercise: $117.58From: 2023-02-18Exp: 2032-02-17→ Common Shares (48,852 underlying) - Tax Payment
Common shares without par value
2022-02-19$116.79/sh−595$69,490→ 18,547 total - Award
Common shares without par value
2022-02-18+10,482→ 19,142 total
Footnotes (2)
- [F1]These shares represent a performance-based restricted stock award under the Abbott Laboratories 2017 Incentive Stock Program. The award has a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The award includes the right to have shares withheld for tax purposes.
- [F2]Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 16,284 on February 18, 2023, 16,284 on February 18, 2024, and 16,284 on February 18, 2025.